



en 7684
AP 7

Attorney Docket: UNI.19

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: JIA ET AL.) EXAMINER: MELLER, M.
SERIAL NUMBER: 10/091,362) ART UNIT: 1654
FILING DATE: MARCH 1, 2002)
TITLE: IDENTIFICATION OF FREE-)
B-RING FLAVONOIDS AS)
POTENT COX-2)
INHIBITORS)

Mail Stop:
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Applicant calls the Examiner's attention to the patents and publications listed on the attached Form PTO-1449, copies of required documents enclosed, which may be material to examination of the above identified application. In accordance with 37 CFR § 1.98(a)(3)(ii), an English translation of Kim et al. (1990) Yakhak Hoeji 34(5):348-364 is provided.

TIME OF TRANSMITTAL

This Information Disclosure Statement is being submitted under 37 CFR §1.97(d). This Statement is filed after a final action under 37 CFR §1.113, after a notice of allowance under 37 CFR §1.311, or after an action that otherwise closes prosecution on the merits, but before or simultaneously with the payment of the issue fee.

Certification under 37 CFR §1.97(e)(1)

The undersigned hereby certified that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.


09/23/2005 RFEKADUI 00000016 10091362

01 FC:1806

180.00 OP

37 CFR 1.8
CERTIFICATE OF MAILING


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on 19 SEPTEMBER 2005

Signature: 
Name: Lisa S. Susser

Submitted herewith is a check in the amount of \$180.00 in accordance with 37 CFR §1.17(p). It is believed that no other fees are due with this submission. The undersigned hereby authorizes the charge of any deficiency of fees submitted herewith, or the credit of any overpayment, to deposit account number 19-5117.

The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. This listed patents and publications are believed of interest herein and consideration and citation of as interest by Examiner is respectfully requested.

Respectfully submitted,


Rosemary Kellogg, #39,726
Swanson & Bratschun, LLC
1745 Shea Center Drive, Suite 330
Highlands Ranch, Colorado 80129
303.268.0066
303.268.0065 (FAX)

cc: Unigen Pharmaceuticals, Inc.
S:\CLIENTFOLDERS\UNIGEN PHARMACEUTICALS\UNI19\SUPPIDS02.DOC



PTO-1449 US DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE List of Information Cited by Applicant Page 1 of 1	ATTORNEY DOCKET NUMBER	SERIAL NUMBER
	UNI.19	10/091,362
	APPLICANT JIA ET AL.	
	FILING DATE	GROUP ART UNIT
	MARCH 1, 2002	1654

US PATENT DOCUMENTS							
EXAM INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUBCLS	FILE DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
	AO						
	AP						
	AQ						
	AR						
	AS						
	AT						

FOREIGN PATENT DOCUMENTS							
EXAM INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUBCLS	TRANS?
	AU						
	AV						
	AW						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
AX	Kim et al. (1990) Yakhak Hoeji 34(5):348-364
AY	
AZ	
EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	